Contributing writer · PharmD, RPh
Rayan is a pharmacist, life science communicator, and health policy researcher with a deep interest in ensuring patient access to innovative and life-changing therapies. She obtained her PharmD at Rosalind Franklin…
Rayan is a pharmacist, life science communicator, and health policy researcher with a deep interest in ensuring patient access to innovative and life-changing therapies. She obtained her PharmD at Rosalind Franklin College of Pharmacy and completed a postdoctoral fellowship focused on Health Policy & Communications at the National Pharmaceutical Council (NPC) in conjunction with Rutgers University. During her time at NPC, Rayan published HEOR-relevant research (e.g., on the Inflation Reduction Act, patient-focused drug development, and oncology access) in peer-reviewed journals like Pharmacoeconomics Open and Therapeutic Innovation & Regulatory Science. Rayan also supported the research team’s health policy and economic research projects, including abstract and poster development for conferences like AMCP, ISPOR, and ASCO. For the Rutgers portion of the fellowship, Rayan was an adjunct faculty member and led research projects in business development and health policy topics like alternative payment models (APMs) and the 340B program. Rayan continues to work at the intersection of innovative pharmaceutical advancement and communications as Chief Medical Writer at TheBrief.Health.
PharmD, RPh
Innovation & Devices
An FDA Class I recall covers Luna G3 APAP model LG3600 with specified firmware. Clinicians and suppliers need to identify exposed patients and protect continuity of positive airway pressure therapy.
Rayan Salih · 6 min read
Innovation & Devices
Certain ResMed Astral 100 and 150 ventilators require correction because supercapacitor leakage may contribute to failure. Ventilator-dependent patients need prompt device checks and reliable backup plans.
Rayan Salih · 6 min read
Endocrinology & Metabolism
The Endocrine Society advises against routine brain MRI for girls ages 6–8 and boys ages 8–9 with central precocious puberty and no neurologic signs.
Rayan Salih · 6 min read
Oncology
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy progression.
Rayan Salih · 6 min read
Cardiology
ITACS addresses IV iron before cardiac surgery, but the supplied citation lacks the numerical results needed to determine whether it reduces transfusion or improves recovery.
Rayan Salih · 6 min read
Oncology
FDA accelerated approval makes tumor HER2 kinase-domain mutation status treatment-defining for eligible adults with previously treated, advanced nonsquamous NSCLC.
Rayan Salih · 7 min read
Innovation & Devices
A Class I recall of certain Impella CP SmartAssist sets follows persistent low-purge-pressure alarms that may interrupt support. Hospitals should identify affected inventory and plan for monitored pump exchange.
Rayan Salih · 6 min read
Neurology
The FDA approved apitegromab for patients aged 2 years or older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.
Rayan Salih · 7 min read
Women's Health
The FDA approved first-line sacituzumab govitecan alone for patients unable to receive checkpoint inhibition and with pembrolizumab for PD-L1–positive advanced triple-negative breast cancer.
Rayan Salih · 7 min read
Cardiology
Across 35 randomized trials, high-dose omega-3 treatment was associated with higher atrial fibrillation risk. The absolute increase was modest but relevant for cardiovascular patients.
Rayan Salih · 6 min read
Cardiology
Across randomized heart-failure trials, SGLT2 inhibitors most reliably reduce worsening heart failure and cardiovascular death. Evidence for lower all-cause mortality is less secure.
Rayan Salih · 7 min read
Oncology
MATTERHORN found better event-free survival and pathologic response with perioperative durvalumab plus FLOT for resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · 7 min read
Women's Health
The FDA approved imlunestrant plus abemaciclib for adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer that progressed after endocrine therapy.
Rayan Salih · 6 min read
Clinical Briefs
The FDA reported 184 serious injuries and no deaths involving specified Medtronic and Given Imaging esophageal pH capsule delivery devices. Gastroenterology services should review inventory, workflows and follow-up.
Rayan Salih · 7 min read
Cardiology
FDA approval adds baxdrostat as an aldosterone-targeted option for adults whose hypertension remains uncontrolled on combination therapy.
Rayan Salih · 7 min read
Infectious Disease
WHO has issued a unified framework for clinicians and outbreak teams managing Ebola and Marburg disease, linking supportive care with infection prevention, workforce protection, and coordinated response.
Rayan Salih · 7 min read
Oncology
Interim phase 3 results favor adding sacituzumab tirumotecan to first-line pembrolizumab for PD-L1-positive advanced NSCLC, but survival, safety and generalizability remain unsettled.
Rayan Salih · 6 min read
Oncology
FDA accelerated approval applies to previously treated, advanced non-squamous NSCLC with qualifying activating mutations in the HER2 tyrosine kinase domain—not every ERBB2 alteration.
Rayan Salih · 6 min read
Infectious Disease
A CDC alert describes increased reports of human rabies exposures nationwide. Clinicians need a rapid workflow for exposure assessment, public health consultation and correctly delivered prophylaxis.
Rayan Salih · 7 min read
Oncology
The FDA approved an allogeneic regulatory T-cell therapy for adults with hematologic malignancies undergoing matched-donor stem cell transplantation. Programs must assess eligibility, logistics and safety readiness.
Rayan Salih · 6 min read
Oncology
Ivonescimab plus chemotherapy prolonged median overall survival after EGFR-TKI therapy, but toxicity, generalizability and US regulatory status shape its relevance.
Rayan Salih · 7 min read
Innovation & Devices
The FDA has cleared Dexcom Stelo for over-the-counter use in people aged 2 years and older who do not use insulin, extending nonprescription continuous glucose monitoring to children.
Rayan Salih · 6 min read
Health Policy
An FDA-posted recall of one morphine injection lot shows why hospitals need closed-loop alerts, secure quarantine and lot-level verification when a mislabeled container may hold hydromorphone.
Rayan Salih · 6 min read
Cardiology
In a randomized trial, acoramidis preserved patient-reported health status and reduced cardiovascular hospitalizations over 30 months in adults with transthyretin amyloid cardiomyopathy.
Rayan Salih · 7 min read
Cardiology
A randomized trial reported that stopping primary-prevention statins in adults 75 or older was noninferior to continuation for 3-year mortality. The confidence interval is central to applying that result.
Rayan Salih · 6 min read
Women's Health
An individual-patient-data meta-analysis found no improvement in live birth or clinical pregnancy when intrauterine hCG was given before embryo transfer.
Rayan Salih · 6 min read
Oncology
The FDA granted accelerated approval to sevabertinib for adults with advanced nonsquamous NSCLC harboring activating HER2 tyrosine kinase domain mutations, making validated genomic identification central to treatment selection.
Rayan Salih · 6 min read
Clinical Briefs
An FDA-posted recall covers an affected lot of tocilizumab-aazg (Tyenne) vials because of possible glass particles. Clinicians should separate patient assessment from inventory control.
Rayan Salih · 6 min read
Oncology
Accelerated approval places zidesamtinib after a prior ROS1 tyrosine kinase inhibitor, with reported activity in systemic and intracranial disease but no randomized evidence yet.
Rayan Salih · 6 min read
Women's Health
Updated ACOG guidance retains a 4-mm endometrial thickness cutoff while clarifying when ultrasound is insufficient and tissue evaluation is needed.
Rayan Salih · 6 min read